德维喜DOVC品牌怎么样 申请店铺

我要投票 德维喜DOVC在其他行业中的票数:604 更新时间:2026-01-24
德维喜DOVC是哪个国家的品牌?「德维喜DOVC」是 东北制药集团股份有限公司 旗下著名品牌。该品牌发源于辽宁省沈阳市,由创始人魏海军在1993-06-10期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力德维喜DOVC品牌出海!将品牌入驻外推网,定制德维喜DOVC品牌推广信息,可以显著提高德维喜DOVC产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

德维喜DOVC怎么样

创始于1993年,知名维生素品牌,覆盖医药研发、制造、分销全产业链条,以化学原料药为主的大型综合性制药企业


东北制药集团股份有限公司(简称“东北制药”,股票代码:000597),是辽宁方大集团实业有限公司(简称“方大集团”)旗下上市公司。公司前身为东北制药总厂,始建于1946年,曾援建全国19省市52家医药企业,向外输送干部1300多人。

目前,东北制药拥有化学原料药、化学制剂、医药商业、医药工程、生物医药等主要业务板块,覆盖医药研发、制造、分销全产业链条,员工队伍9300余人,总资产120亿元。公司主要生产维生素系列药品、抗感染系统用药、妇产科系统用药、消化系统用药、泌尿系统用药、抗病毒系列用药、心脑血管系列用药、镇痛镇咳系列用药、生物诊断系列、大健康领域系列等十大系列精品,400多种化学原料药、医药中间体和制剂产品,主导产品远销100多个国家和地区。

公司拥有强大的产品制造体系。制剂生产基地占地18万平方米,拥有生产线30余条,年产能100亿片(支、丸、粒、枚、瓶)。原料药生产基地占地91万平方米,是国家大宗原料药和医药中间体智能制造示范工厂,主要产品包括维生素C及系列、左旋肉碱系列、磷霉素系列、吡拉西坦、卡前列甲酯、金刚烷胺、硫糖铝、黄连素、氯霉素等,并向下游东北制药制剂产业链延伸,形成难以复制的综合竞争优势。

东北制药不仅是中国重要的药品生产与出口基地,还设有药物研究院、工程设计公司、装备制造安装公司、国际贸易公司、计量检测公司、危化品运输公司等各独立业务公司。

东北制药医药商业业务网络覆盖辽宁全部地级市县,并向东北三省延伸,东北大药房拥有百余家连锁店,医药电商业务实现线上线下一体化,商业模式创新持续推进。


Founded in 1993, it is a well-known vitamin brand, covering the whole industrial chain of pharmaceutical research and development, manufacturing and distribution. Northeast Pharmaceutical Group Co., Ltd., a large comprehensive pharmaceutical enterprise mainly engaged in chemical APIs (hereinafter referred to as "Northeast Pharmaceutical", stock code: 000597), is a listed company under Liaoning Fangda Group Industry Co., Ltd. (hereinafter referred to as "Fangda group"). The company, formerly known as the Northeast Pharmaceutical General Factory, was founded in 1946. It has assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and has sent more than 1300 cadres. At present, Northeast Pharmaceutical has major business sectors such as chemical APIs, chemicals, pharmaceutical commerce, pharmaceutical engineering, biomedicine, covering the whole industrial chain of pharmaceutical research and development, manufacturing, distribution, with more than 9300 employees and a total asset of 12 billion yuan. The company mainly produces ten series of high-quality products, including vitamin series, anti infection system medicine, gynecology and obstetrics system medicine, digestive system medicine, urinary system medicine, anti-virus series medicine, cardiovascular and cerebrovascular series medicine, analgesia and antitussive series medicine, biological diagnosis series, large health field series, more than 400 kinds of chemical APIs, pharmaceutical intermediates and preparation products, leading products It is exported to more than 100 countries and regions. The company has a strong product manufacturing system. The preparation production base covers an area of 180000 square meters, with more than 30 production lines and an annual production capacity of 10 billion tablets (pills, granules, tablets, bottles). The API production base covers an area of 910000 square meters. It is a national bulk API and pharmaceutical intermediate intelligent manufacturing demonstration factory. Its main products include vitamin C and series, L-carnitine series, fosfomycin series, piracetam, carboprost methyl ester, amantadine, sucralfate, berberine, chloramphenicol, etc. and it extends to the downstream Northeast Pharmaceutical industry chain, forming a hard to replicate Comprehensive competitive advantage. Northeast Pharmaceutical is not only an important pharmaceutical production and export base in China, but also has independent business companies such as pharmaceutical research institute, engineering design company, equipment manufacturing and installation company, international trade company, measurement and testing company, dangerous chemicals transportation company, etc. The Northeast Pharmaceutical business network covers all prefecture level cities and counties in Liaoning, and extends to three provinces in Northeast China. The Northeast pharmacy has more than 100 chain stores. The online and offline integration of pharmaceutical e-commerce business is realized, and the innovation of business model is continuously promoted.

本文链接: https://brand.waitui.com/aa403ad85.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前涨跌不一,Arm涨超2%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,Arm涨超2%,英伟达涨超1%,谷歌涨0.1%,微软涨0.06%;特斯拉跌0.17%,奈飞跌0.11%,亚马逊跌0.07%,苹果跌0.03%。

48分钟前

热门中概股美股盘前涨跌互现,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前涨跌互现,截至发稿,阿里巴巴、京东跌超1%,小鹏汽车跌近1%,网易跌0.48%,蔚来跌0.21%;百度涨超1%,拼多多涨0.75%,理想汽车涨0.42%,B站涨0.09%。

48分钟前

晶升股份:拟购买为准智能100%股份,交易作价8.57亿元

36氪获悉,晶升股份公告,公司拟通过发行股份及支付现金的方式购买本尚科技等10名交易对方持有的为准智能100%股份,同时募集配套资金。为准智能100%股份的交易作价为8.57亿元。本次交易构成关联交易和重大资产重组,但不构成重组上市。交易完成后,为准智能将成为上市公司控股子公司。

48分钟前

天合光能:将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”

36氪获悉,天合光能公告,公司拟缩减“年产35GW直拉单晶项目”的募集资金投资金额,不再实施二期15GW项目,并将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”。新项目预计2026年底建成并投入运营。公司表示,本次变更有利于提高募集资金使用效率,合理优化资源配置,巩固市场地位,不会对公司正常经营产生不利影响。该事项尚需提交公司股东会和债券持有人会议审议通过后方可实施。

48分钟前

宝洁第二财季净销售额222亿美元,同比增长1%

当地时间1月22日,宝洁公司发布2026财年第二季度(2025年10-12月)财报。财报显示,第二财季净销售额为222亿美元,同比增长1%;摊薄后每股净收益为1.78美元,同比下降5%。该公司维持2026财年总销售额同比增长1%至5%的指引区间,将2026财年摊薄后每股净收益增长指引从原先的3%-9%调整至1%-6%。(界面)

48分钟前

本页详细列出关于德维喜DOVC的品牌信息,含品牌所属公司介绍,德维喜DOVC所处行业的品牌地位及优势。
咨询